Skip to main content
. 2022 Feb 8;10(2):e003804. doi: 10.1136/jitc-2021-003804

Figure 4.

Figure 4

Functional capacity of CD38KO NK cells can be altered by electroporation with CD16-158V mRNA. (A) Representative flow cytometry plots and (B), pooled data of relative expression of CD16 in CD38WT and CD38KO NK cells 24 hours after mRNA electroporation (n=3 donors). (C) NK cell degranulation (measured by CD107a) by CD16-158V mRNA-EP NK cells compared with non-EP NK cells following coculture with Raji cells with or without rituximab (RITUX) 24 hours after electroporation (n=3 donors). (D) DARA-mediated ADCC by CD16-158V mRNA-EP NK cells compared with non-EP NK cells assessed against NCI-H929 myeloma target cells at various effector-to-target (E:T) ratios 24 hours after electroporation (n=3 donors). Statistics determined with the Student’s t-test, two tailed, ns=not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. ADCC, antibody-dependent cellular cytotoxicity; DARA, daratumumab; EP; electroporated; KO, knockout; WT, wild type; NK, natural killer.